# Chinagene Tech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/chinagene-tech

- Industry: Healthcare
- Headquarters: Beijing, China
- Website: www.chinagene.cc
- Total disclosed funding: $16M
- Latest round: Series B (Sep 16, 2025)
- Investors on record: 6

## About

Founded in 2016 and based in Beijing China, Chinagene Tech is a biotech company that focuses on clinical gene diagnosis, fertility prevention, and gene therapy drug development. The founder teams of the company have been researching hereditary eye disease genes for 20 years, its genetic diagnosis platform for hereditary eye diseases has the qualification of a third-party medical clinic. The company completed 2 rounds of funding. In July 2017, its Medical Testing Laboratory was established. In March 2019, the company built three technology platforms for drug development. In October 2023, Chinagene Tech raised series B funding led by new investor Kunlun VC, with participation from another new investor GP Capital. In July 2025, it closed a series B++ funding. In September 2025, Chinagene Tech closed a series B+ funding from returning investor Lapam Capital. 
The company provides patients with gene drugs, eye gene testing services and products, maternity prevention inquiry solutions, and gene knowledge classes. Its gene detection of retinitis pigmentosa contains advantages such as high coverage, high capture efficiency, and comprehensive detection of variant types. Based on the two basic research platforms of gene replacement and editing therapy, the company has launched 4 gene replacement therapy R&D pipelines and 2 gene editing therapy R&D pipelines. Among them, the ZVS101e project will officially start clinical trials, and ZVS203e, ZVS204e are preparing to declare Clinical Trials. 
Revenue primarily comes from development and provision of gene drugs, therapies, genetic testing service and related healthcare solutions such as gene editing and replacement platforms. The company will further advance its technological breakthroughs and clinical applications in ophthalmic gene therapy.

## Funding rounds

- Series B, Sep 16, 2025 — Lapam Capital
- Series B, Oct 7, 2023 — GP Capital, Shanhai Capital
- Series A, Mar 30, 2022, $16M — Lapam Capital, Yingke Private Equity, HY Capital, Junci Investment

## Investors

- Lapam Capital (https://capitalatlas.ai/funds/lapam-capital) — Series A, Series B
- Yingke Private Equity (https://capitalatlas.ai/funds/yingke-private-equity) — Series A
- HY Capital (https://capitalatlas.ai/funds/hy-capital) — Series A
- Junci Investment (https://capitalatlas.ai/funds/junci-investment) — Series A
- GP Capital (https://capitalatlas.ai/funds/gp-capital) — Series B
- Shanhai Capital (https://capitalatlas.ai/funds/shanhai-capital) — Series B